---

$5.90

-0.1050 ( -1.75% ) 441.0K

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2023-11-17	Buy	6500.00	Schmid John P.
2023-11-17	Buy	30769.00	Shannon John Patrick Jr
2023-11-15	Buy	6370.00	PERSKY MARLA
2023-08-09	Buy	10000.00	Edick Paul R